EPHB2

(redirected from CAPB)
Also found in: Acronyms.

EPHB2

A gene on chromosome 1p36.1-p35 that encodes a member of the ephrin-B receptor subfamily of receptor tyrosine kinases, which “promiscuously” bind membrane-bound ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighbouring cells. EPHB2 functions in axon guidance during development, guiding commissural axons and forming a major interhemispheric connection between the two temporal lobes of the cerebral cortex. EPHB2 is also involved in the guidance of contralateral inner ear efferent growth cones at the midline, and of retinal ganglion cell axons to the optic disk. It also regulates dendritic spines development and maturation, and it stimulates the formation of excitatory synapses.

Activation of EPHB2 by EFNB1 abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. EPHB2 also controls other aspects of development, including angiogenesis, palate development, as well as inner ear development by regulating endolymph production. It may act as a tumour suppressor.

Molecular pathology
Defects in EPHB2 have been linked to prostate cancer.
References in periodicals archive ?
Definition 1--Consolidation: A consolidation is an improvement of the CAPB of at least 1.
5 per cent of GDP improvement in the CAPB was chosen for three reasons.
Definition 2--Success: A consolidation in line with Definition 1 is deemed successful if the following condition applies; in the three years after the end of the consolidation episode the CAPB does not deteriorate by more than 0.
In close to 70 per cent of the years featuring a consolidation episode in line with Definition 1, the CAPB improved by 1.
Almost 30 per cent of the consolidation years recorded for the 'new' EU member states gave rise to an annual improvement of the CAPB of 3 per cent of GDP or more.
The estimated coefficient of the change in the CAPB is not statistically significant, and the negative sign suggests that more contained adjustments are not more likely to be reversed.
The foaming properties of shampoo model formulation without and with 2% active SLL-FB as an additive on the top of 12% active SLES-2 and 3% active CAPB were studied in a salon using a standard salon half-head test method.
At 2% active concentration, sodium stearoyl lactylate (SSL-CG) and sodium lauroyl lactylate (SLL-FB) demonstrated better stability in body wash formulations based on 12% active SLES-2 and 3% active CAPB.
00 (and) CAPB (45% active) PEG-120 methyl glucose dioleate 1.